1. Scrip
  2. >>Business

Finance Watch: Prepare For September IPOs To Rebound From August Slowdown

H1 Saw $10.2bn In COVID-19 Financings

 
• By Mandy Jackson

Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.

Finance Watch Image

The IPO market slowed down in August but it looks like first-time offerings will regain their momentum in September, still on track for 2021 to be the most active year since the dot-com boom year of 2000, according to the IPO-tracking firm Renaissance Capital.

The biopharma industry has been a big driver in terms of the number of IPOs in the US this year with 84 offerings as of mid-August when RenovoRx, Inc. went public, grossing $16.65m. (Also see "Finance Watch: Venture Capital, Debt Financings Led Fundraising Surge In Q2" - Scrip, 27 August, 2021

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.